The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Before I give my recommendation I want to visit with the charts and indicators.
In addition to the yield let's check out the charts of ABBV.
Here's how to play the stock now.
Traders need to respect this price strength.
I thought last night's debate was pretty frightening when it comes to managed care, banking, airlines, and drugs.
Ingredion recently inched up its new quarterly dividend, and while the nation's corn production woes may cause a headwind for the company, its ample cash offers security.
Sellers of the drugstore chain's stock have been aggressive for months and the overall technical picture is weak.
There is no upside leadership at present, although a few defensive groups such as pharmaceuticals are seeing some interest.
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.